Johnson&Johnson Opsynvi single tablet combination therapy approved by FDA
我放心你带套猛
发表于 2024-3-23 17:13:08
214
0
0
Johnson&Johnson announced on the 23rd that the US FDA has approved its Opsynvi monotherapy combination therapy for long-term treatment of adult patients with pulmonary arterial hypertension (PAH) classified as II-III by the World Health Organization (WHO) Functional Classification (FC). The approval of Opsynvi enables Johnson&Johnson's PAH product portfolio to cover all PAH targeted pathways recommended by the guidelines. It is reported that Opsynvi is the first FDA approved PAH single tablet combination therapy. The approval of Opsynvi by the US FDA is mainly based on the results of key Phase 3 clinical studies of A DUE, in which Opsynvi demonstrates that patients have a greater reduction in pulmonary vascular resistance (PVR) after 16 weeks of treatment compared to monotherapy with tadalafil or macitabine.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Exploring the "Golden Nine Silver Ten" in the Car Market: Car Companies Play a Promotion Combination Fist, and New Energy Sales Continuously Rise
- Argentina's economic experiment is about to take place! Today, the global market will witness the impact of "shock therapy"
- AstraZeneca will acquire Genxi Biotechnology to deepen the layout of cell therapy in the fields of tumors and autoimmune diseases
- 12 weeks of weight loss exceeding 13%. Novo Nordisk's oral therapy has been declared clinically in China
- Baishime Squibb CAR-T therapy approved by the US FDA
- GSK is betting 1.45 billion euros on the imminent outbreak of cross generational business opportunities in mRNA therapy categories?
- Modner claims that the company has reached a joint agreement with Mitsubishi Tanabe Pharmaceuticals to promote the company's mRNA respiratory vaccine portfolio in Japan
- Is the beef fillet at the small ingredient counter gone? Haidilao: Free selection available on tablets
-
【英偉達の需要が高すぎる?SKハイニックス:黄仁勲がHBM 4チップの6カ月前納入を要求!】SKハイニックスの崔泰源(チェ・テウォン)会長は月曜日、インビダーの黄仁勲(ファン・インフン)CEOが同社の次世代高帯域 ...
- 琳271
- 前天 17:54
- 支持
- 反对
- 回复
- 收藏
-
ファイザーが前立腺がんを治療する革新薬テゼナ& ;reg;(TALZENNA®,一般名:トルエンスルホン酸タラゾールパーリカプセル)は2024年10月29日に国家薬品監督管理局(NMPA)の承認を得て、HRR遺伝子突然変異 ...
- 什么大师特
- 昨天 17:41
- 支持
- 反对
- 回复
- 收藏
-
南方財経は11月5日、中央テレビのニュースによると、現地時間11月5日、米ボーイング社のストライキ労働者が59%の投票結果で新たな賃金協定を受け入れ、7週間にわたるストライキを終えた。ストライキ労働者は11月12 ...
- Dubssgshbsbdhd
- 昨天 16:27
- 支持
- 反对
- 回复
- 收藏
-
【マスクはテスラが携帯電話を作ることに応えた:作れるが作らないアップルとグーグルが悪さをしない限り】現地時間11月5日、有名ポッドキャストのジョローガン氏のインタビューに応じ、「携帯電話を作るのは私たち ...
- 波大老师
- 昨天 14:41
- 支持
- 反对
- 回复
- 收藏